Global Antihistamines Travel Sickness Drugs Market Size By Type (Adults, Children), By Application (Hospitals, Drugstores), By Region, And Segment Forecasts, 2023 to 2032

The Global Antihistamines Travel Sickness Drugs Market was valued at USD 890 million in 2023 and is projected to reach USD 1.46 billion by 2031, growing at a CAGR of 6.5% during the forecast period from 2023 to 2031. This growth is primarily driven by the increasing incidence of motion sickness due to rising travel frequency, growing awareness of preventive medications, and the widespread availability of over-the-counter antihistamines. These drugs, such as meclizine, diphenhydramine, and promethazine, are preferred for their efficacy in preventing nausea, vomiting, and dizziness associated with motion sickness across road, air, and sea travel.

Drivers

1. Rising Global Travel and Tourism:

The surge in international and domestic travel, especially post-pandemic, has elevated the occurrence of travel-related nausea and dizziness, boosting the demand for antihistamines used in motion sickness treatment.

2. Availability of OTC Medications:

Antihistamines used for travel sickness are widely available over the counter (OTC), making them accessible without prescriptions and encouraging frequent use among consumers.

3. Expansion in Geriatric and Pediatric Populations:

With higher susceptibility to motion sickness in elderly and young populations, pharmaceutical companies are increasingly focusing on age-specific formulations, propelling market expansion.

Restraints

1. Side Effects and Drowsiness:

Common side effects such as drowsiness, dry mouth, and blurred vision associated with antihistamines can deter regular usage, especially among individuals operating machinery or driving.

2. Limited Awareness in Low-Income Regions:

In developing economies, the lack of awareness about preventive medications for motion sickness remains a barrier to market growth.

Opportunity

1. Development of Non-Sedative Formulations:

Pharmaceutical innovations focusing on second-generation antihistamines that reduce drowsiness and other side effects offer a promising avenue for market expansion.

2. Growth of E-commerce and Telehealth Channels:

The increasing adoption of digital pharmacies and teleconsultation services is enhancing product accessibility and consumer outreach, particularly in remote and rural areas.

Market by System Type Insights

First-generation antihistamines such as diphenhydramine and promethazine accounted for the largest market share in 2023 due to their strong anti-nausea properties and quick onset of action. However, second-generation antihistamines are expected to witness faster growth owing to their minimal sedative effects and improved safety profile, especially among working individuals and children.

Market by End-use Insights

In terms of end-use, over-the-counter (OTC) retail pharmacies led the market in 2023. Consumers prefer OTC channels for their convenience, accessibility, and affordability. Meanwhile, the hospital pharmacy segment is anticipated to grow steadily, driven by travel-related consultations and prescriptions for individuals with chronic or recurrent motion sickness.

Market by Regional Insights

North America dominated the global antihistamines travel sickness drugs market in 2023, driven by high travel activity, well-established pharmaceutical infrastructure, and strong consumer awareness. Asia-Pacific is expected to exhibit the fastest CAGR during the forecast period, fueled by a booming tourism sector, rising disposable incomes, and expanding retail pharmacy networks in countries like India, China, and Thailand.

Competitive Scenario

Key players in the market include Pfizer Inc., Johnson & Johnson, Sanofi S.A., GlaxoSmithKline plc, Bayer AG, Prestige Consumer Healthcare Inc., and WellSpring Pharmaceutical Corporation. These companies are focusing on portfolio expansion, non-sedative formulations, and e-commerce integration.

Recent Developments:

2023: GlaxoSmithKline launched a new non-drowsy antihistamine patch for motion sickness prevention.

2024: Sanofi expanded its OTC distribution channels through strategic e-commerce partnerships in Asia-Pacific.

2025: Pfizer received regulatory approval for a pediatric chewable antihistamine tablet in Europe targeting travel sickness symptoms.

Scope of Work – Global Antihistamines Travel Sickness Drugs Market

Key Market Developments

2023: GSK introduced a transdermal antihistamine patch for motion sickness with improved compliance.

2024: Bayer partnered with leading online health platforms to enhance product visibility and sales in Southeast Asia.

2025: Johnson & Johnson launched an extended-release antihistamine capsule targeting long-haul travelers.

FAQs

1) What is the current market size of the Global Antihistamines Travel Sickness Drugs Market?

The market was valued at USD 890 million in 2023.

2) What is the major growth driver of the Global Antihistamines Travel Sickness Drugs Market?

The primary growth driver is the rising frequency of global travel and the increasing use of OTC antihistamines for motion sickness prevention.

3) Which is the largest region during the forecast period in the Global Antihistamines Travel Sickness Drugs Market?

North America holds the largest market share, while Asia-Pacific is expected to grow the fastest.

4) Which segment accounted for the largest market share in Global Antihistamines Travel Sickness Drugs Market?

The first-generation antihistamines segment accounted for the largest share in 2023.

5) Who are the key market players in the Global Antihistamines Travel Sickness Drugs Market?

Key players include Pfizer Inc., Sanofi S.A., GlaxoSmithKline plc, Johnson & Johnson, and Bayer AG.